Bildkälla: Stockfoto

Alzecure Q3 2022: Our comment - Redeye

Redeye comments on Alzecure’s Q3 report, which came in as expected. We also comment on the announced rights issue and for now reiterate our base case.

Redeye comments on Alzecure’s Q3 report, which came in as expected. We also comment on the announced rights issue and for now reiterate our base case.
Börsvärldens nyhetsbrev
ANNONSER